Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.59 |
| ▸ | PPARA | Q07869 | 7/20 | 0.58 |
| ▸ | PPARG | P37231 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | HTR2A | P28223 | 2/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21413783 | 0.83 | ELANE (0.67) | ELANEPPARAPPARGCYP1A2CYP3A4 | |
| SCHEMBL4755280 | 0.82 | PPARA (0.64) | ELANEPPARAPPARGCYP1A2CYP3A4 | |
| SCHEMBL2017810 | 0.82 | ELANE (0.65) | ELANEPPARAPPARGCYP1A2CYP3A4 | |
| SCHEMBL24697056 | 0.81 | PPARA (0.53) | PPARAPPARGCYP1A2CYP3A4KMT2A | |
| Dulofibrate SCHEMBL2110601 | 0.81 | PPARA (0.68) | ELANEPPARAPPARGCYP1A2CYP3A4 | |
| SCHEMBL24697058 | 0.81 | PPARA (0.52) | PPARAPPARGCYP1A2CYP3A4KMT2A | |
| SCHEMBL11566049 | 0.80 | MAPT (0.68) | PPARAPPARGCYP1A2CYP3A4KMT2A | |
| SCHEMBL12573935 | 0.79 | PPARA (0.62) | ELANEPPARAPPARGCYP1A2CYP3A4 | |
| SCHEMBL1810147 | 0.78 | SRD5A2 (0.69) | TSHRMAPTMAPK1LMNATDP1 | |
| SCHEMBL24696708 | 0.77 | KMT2A (0.50) | PPARAPPARGCYP1A2CYP3A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292289-A1 | TREATMENT OF METABOLIC SYNDROME WITH NOVEL AMIDES | AMPLA PHARMACEUTICALS INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292289-A1 | TREATMENT OF METABOLIC SYNDROME WITH NOVEL AMIDES | AMPLA PHARMACEUTICALS INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292289-A1 | TREATMENT OF METABOLIC SYNDROME WITH NOVEL AMIDES | AMPLA PHARMACEUTICALS INC. (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2009073138-A2 | TREATMENT OF METABOLIC SYNDROME WITH NOVEL AMIDES | AMPLA PHARMACEUTICALS INC. (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292289-A1 | TREATMENT OF METABOLIC SYNDROME WITH NOVEL AMIDES | GPR119, CPT1A, GLS2 | ELANE 2276/4885PPARA 147/4885PPARG 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.